Rucaparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Rucaparib (ncit:C137800)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
Sensitivity (+) BRCA1 pathogenic variants Ovarian Epithelial Tumor Rucaparib
Sensitivity (+) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
Sensitivity (+) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
Sensitivity (+) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
Sensitivity (+) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
Sensitivity (+) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
Sensitivity (+) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
Sensitivity (+) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib